OOIR: Observatory of International Research

Papers

(The H4-Index of Haematologica is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Pediatric acute lymphoblastic leukemia	259
The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy	194
International recommendations on the diagnosis and treatment of acquired hemophilia A	176
APR-246 induces early cell death by ferroptosis in acute myeloid leukemia	97
Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia	93
Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma	89
One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors	88
Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial	84
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens	76
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia	74
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma	74
Multiple myeloma: the (r)evolution of current therapy and a glance into future	71
Acquired von Willebrand syndrome: focused for hematologists	70
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models	70
Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion	64
CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide	63
Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition	62
Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study	61
History of hematopoietic cell transplantation: challenges and progress	60
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT	58
An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study	58
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE t	57
Geriatric assessment in older patients with a hematologic malignancy: a systematic review	55
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria	55
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis	53

Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia	51
Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies	50
Complement C5 inhibition in patients with COVID-19 - a promising target?	50
A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies	48
Myelodysplastic syndromes: moving towards personalized management	48
Post-mortem findings in vaccine-induced thrombotic thombocytopenia	47
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients	47
ABO blood groups are not associated with risk of acquiring the SARS-CoV-2 infection in young adults	46
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma	46
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies	46
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma	44
VEXAS syndrome in a female patient with constitutional 45,X (Turner syndrome)	44
MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma	44
Targeting the tumor microenvironment in chronic lymphocytic leukemia	43
Thromboinflammatory mechanisms in sickle cell disease - challenging the hemostatic balance	43
Inherited thrombocytopenias: history, advances and perspectives	43
Potential targeting of FLT3 acute myeloid leukemia	43
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913	43
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression	43